August 1991

Immunogenicity of Tetravalent Rhesus Rotavirus Vaccine Administered With Buffer and Oral Polio Vaccine

Author Affiliations

From the Department of Pediatrics, Emory University School of Medicine, Atlanta, Ga (Ms Ing, Drs Glass and Wilcox, and Ms Simonetti); Viral Gastroenteritis Unit, Respiratory and Enteric Virus Branch, Division of Viral and Rickettsial Diseases, Center for Infectious Diseases, Centers for Disease Control, US Department of Health and Human Services, Public Health Service, Atlanta (Drs Glass and Pallansch and Ms Woods); Wyeth-Ayerst Research, Clinical Research and Development, Philadelphia, Pa (Dr Davidson); and Division of Physical Health, DeKalb County Board of Health, Decatur, Ga (Dr Sievert).

Am J Dis Child. 1991;145(8):892-897. doi:10.1001/archpedi.1991.02160080070023

• Between January and November 1989, we studied 174 infants aged 6 to 16 weeks in a randomized clinical trial to (1) determine the immunogenicity of a single dose of tetravalent rhesus rotavirus vaccine (RRV-TV) when administered with three different buffer regimens: no antacid buffer and small-volume (2.5-mL) and large-volume (30-mL) antacid buffer; and (2) examine the potential interference of RRV-TV on the immune response to oral polio vaccine. Immunogenicity of RRV-TV, measured as a fourfold rise in antibody titers to rotavirus, was similar in the groups receiving small- and large-dose buffer (45% and 49%, respectively) and significantly less in the group that received RRV-TV alone (23%). Administration of RRV-TV with oral polio vaccine did not significantly interfere with the neutralization response of oral polio vaccine poliovirus serotypes 1, 2, or 3, and overall, 29%, 87%, and 24% of the infants had a fourfold rise in titer to each serotype, respectively.

(AJDC. 1991;145:892-897)